Voie excrétrice supérieure : physiologie, physiopathologie des obstructions et explorations fonctionnelles

Normand, L. Le; Buzelin, Jean-Marie; Bouchot, Olivier; Rigaud, J.; Karam, Georges

doi:10.1016/j.anuro.2005.01.002

Cited by 17 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irreversible renal impairment was observed essentially in patients with a delayed diagnosis, suboptimal urological and medical management, or intrinsically severe forms of stone disease. 4,5 Severe forms of nephrolithiasis remain an underestimated cause of potentially avoidable ESRD and the need renal replacement therapy. 6 In our experience, nephrolithiasis related ESRD contributed 0.63% to the total series of patients who started maintenance dialysis therapy at our department of nephrology during a 15 year period.…”

Section: Discussionmentioning

confidence: 99%

Nephrolithiasis-induced end stage renal disease

Ounissi¹

2010

IJNRD

View full text Add to dashboard Cite

Introduction: Nephrolithiasis still remains a too frequent and underappreciated cause of end stage renal disease (ESRD). Methods and patients:Of the entire cohort of 7128 consecutive patients who started maintenance dialysis in our nephrology department between January 1992 and December 2006, a total of 45 patients (26 women, 19 men) had renal stone disease as the cause of ESRD. The type of nephrolithiasis was determined in 45 cases and etiology in 42. The treatment and evolution of stone disease and patient's survival were studied. Results: The overall proportion of nephrolithiasis related ESRD was 0.63%. The mean age was 48.4 years. Infection stones (struvite) accounted for 40%, calcium stones, 26.67% (primary hyperparathyroidism:15.56%; familial hypercalciuria: 4.44%, unknown etiology: 6.66%), primary hyperoxaluria type 1, 17.78% and uric acid lithiasis in 15.56% of cases. The mean delay of the evolution of the stone renal disease to chronic renal failure was 85.8 months. The feminine gender, obesity and elevated alkaline phosphatases 128 IU/L were significantly correlated with fast evolution of ESRD. The median evolution to ESRD was 12 months. The normal body mass index (BMI), medical treatment of stone and primary hyperoxaluria type 1 were correlated with fast evolution to ESRD. All patients were treated by hemodialysis during a mean evolution of 60 months. Sixteen patients died. The patient's survival rate at 1, 3 and 5 years was 97.6, 92.8 and 69% respectively. Hypocalcemia, cardiopathy and normal calcium-phosphate product were significantly correlated with lower survival rate. Conclusion: Severe forms of nephrolithiasis remain an underestimated cause of ESRD. These findings highlight the crucial importance of accurate stone analysis and metabolic evaluation to provide early diagnosis and efficient treatment for conditions leading to ESRD.

show abstract

Section: Discussionmentioning

confidence: 99%

Nephrolithiasis-induced end stage renal disease

Ounissi¹

2010

IJNRD

View full text Add to dashboard Cite

show abstract

“…[2][3][4] The natural course of MS can also be complicated by alterations affecting the upper urinary tract, such as vesico-ureteral reflux, hydronephrosis and loss of kidney function. 5 In patients with MS, urologic conditions can heavily impact the psychological, occupational, domestic and social aspects of quality of life (QoL), limiting liquids intake, sexual activity, and often implies the use of diapers as precautionary measure. 6 Currently, specific and validated questionnaires have been widely used in neurourology, focusing on lower urinary tract symptoms (LUTS) and on their impact on QoL.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous tibial nerve stimulation in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: a historically controlled study

Carilli

Pacini

Serati

et al. 2023

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: Percutaneous tibial nerve stimulation (PTNS) is widely used in the treatment of neurogenic detrusor overactivity (NDO) in multiple sclerosis (MS); however, controlled studies are still lacking. Objective: To assess effectiveness of PTNS in MS patients with NDO unresponsive to pharmacological and behavioural therapies. Methods: MS patients with NDO were enrolled. Inclusion criteria were NDO not responding to pharmacological and behavioural therapies. Exclusion criteria were the presence of relevant comorbidities and urinary tract infections. Patients were evaluated using 3-day bladder diaries and validated questionnaires at baseline, after 4 weeks of educational therapy and after 12 PTNS sessions. The primary outcome measure was the percentage of patients considered responders after the behavioural therapy and after the PTNS in a historical controlled fashion (definition of ‘responder’ was reduction ⩾50% of urgency episodes). Results: A total of 33 patients (26 women, 7 men) were enrolled. Two patients dropped out for reasons not related to the protocol. Two out of 31 patients (6.5%) and 21/29 (72.4%) were considered responders at visits 1 and 2, respectively. In PTNS responders, a statistically significant improvement in both bladder diary results and standardized questionnaire scores was recorded, compared with that obtained with behavioural therapy alone. No serious adverse events were reported. Conclusion: This historically controlled study suggests that PTNS may be effective in improving NDO in MS patients.

show abstract